An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2013
At a glance
- Drugs Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center; 2003-0492).
- 17 Sep 2007 Status changed from in progress to completed.